Study of AB598 Monotherapy and Combination Therapy in Participants With Advanced Cancers
Running, not enrolling · Phase 1
Conditions studied: Advanced Cancer, Advanced Malignancies, Bladder Cancer, Cervical Cancer, Esophageal Cancer, Gastric Cancer, Gastroesophageal-junction Cancer (GEJ), Head and Neck Squamous Cell Carcinoma (HNSCC), Non-Small Cell Lung Cancer (NSCLC), Ovarian Cancer, Renal Cell Carcinoma (RCC), Triple Negative Breast Cancer (TNBC)
In brief
The primary purpose of this study is to assess the safety and tolerability of AB598 in participants with advanced malignancies.
Key facts
- Study ID
- NCT05891171
- Run by
- Arcus Biosciences, Inc.
- People needed
- 40
- Starts
- 2023-10-13
- Expected to finish
- 2027-09-01
- Last updated by the study team
- 2026-07-30
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Research Site — Phoenix, Arizona, United States
- Research Site — Jacksonville, Florida, United States
- Research Site — Lake City, Florida, United States
- Research Site — Hinsdale, Illinois, United States
- Research Site — Detroit, Michigan, United States
- Research Site — Rochester, Minnesota, United States
- Research Site — New Brunswick, New Jersey, United States
- Research Site — Canton, Ohio, United States
- Research Site — Cleveland, Ohio, United States
- Research Site — Irving, Texas, United States
- Research Site — Fairfax, Virginia, United States
- Research Site — Adelaide, Australia
- Research Site — Tainan, Taiwan
- Research Site — Taipei, Taiwan
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.